N-SIDE has signed with Sanofi an amendment to their agreement to use N-SIDE’s risk-based production planning optimization solution
This agreement comes at the successful conclusion of the pilot study conducted by Sanofi and N-SIDE using N-SIDE’s innovative solution to optimize end-to-end production planning at the clinical program level. N-SIDE is happy to continue the collaboration with Sanofi as the project moves into the commercial phase.
CT-PRO is a cutting-edge tool based on optimization algorithms that manage the forecast at the drug substance and drug product level, pooling the needs of multiple clinical trials and taking into account non-clinical demands as well (e.g. stability analysis, commercial launch, etc.). CT-PRO addresses both risk management and cost minimization.